Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,142
  • Shares Outstanding, K 2,626
  • Annual Sales, $ 25,860 K
  • Annual Income, $ -32,090 K
  • 60-Month Beta 0.69
  • Price/Sales 0.05
  • Price/Cash Flow N/A
  • Price/Book 3.61
Trade BIOC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -58.45
  • Most Recent Earnings $-3.50 on 08/14/23
  • Latest Earnings Date 11/20/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3200 +35.91%
on 10/16/23
1.5799 -72.47%
on 09/26/23
-0.9651 (-68.94%)
since 09/22/23
3-Month
0.3200 +35.91%
on 10/16/23
1.8500 -76.49%
on 09/08/23
-1.0151 (-70.01%)
since 07/24/23
52-Week
0.3200 +35.91%
on 10/16/23
27.0000 -98.39%
on 11/07/22
-21.7351 (-98.04%)
since 10/24/22

Most Recent Stories

More News
Biocept Reports 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update....

BIOC : 0.4349 (-13.05%)
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary...

BIOC : 0.4349 (-13.05%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares...

BIOC : 0.4349 (-13.05%)
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan

Biocept, Inc. (NasdaqCM: BIOC ) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of...

BIOC : 0.4349 (-13.05%)
Biocept Reports Third Quarter 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a...

BIOC : 0.4349 (-13.05%)
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately,...

BIOC : 0.4349 (-13.05%)
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic...

BIOC : 0.4349 (-13.05%)
Assure Holdings Corp. (IONM) Reports Q3 Loss, Lags Revenue Estimates

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -28.57% and 17.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

IONM : 0.6490 (-0.15%)
BIOC : 0.4349 (-13.05%)
Agiliti (AGTI) Q3 Earnings Surpass Estimates

Agiliti (AGTI) delivered earnings and revenue surprises of 5.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AGTI : 10.02 (-0.20%)
BIOC : 0.4349 (-13.05%)
Biocept Reports Second Quarter 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business...

BIOC : 0.4349 (-13.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

3rd Resistance Point 0.5733
2nd Resistance Point 0.5317
1st Resistance Point 0.4833
Last Price 0.4349
1st Support Level 0.3933
2nd Support Level 0.3517
3rd Support Level 0.3033

See More

52-Week High 27.0000
Fibonacci 61.8% 16.8082
Fibonacci 50% 13.6600
Fibonacci 38.2% 10.5118
Last Price 0.4349
52-Week Low 0.3200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar